ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1935

Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19

Marion THOMAS1, Maeva MASSON2, Raphaele Seror3, Samuel Bitoun4, Henry DUPUY5, Lazato ESTIBALIZ5, Christophe Richez6, Yannick ALLANORE7 and Jerome AVOUAC8, 1HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, 2CHU Toulouse, Toulouse, France, 3University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 4CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, 5CHU Bordeaux, Bordeaux, France, 6Université de Bordeaux, Bordeaux, France, 7Université Paris Cité, Paris, France, 8Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France

Meeting: ACR Convergence 2023

Keywords: COVID-19, Infection, prevention

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1913–1944) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability of insufficient response to vaccination. The monoclonal antibody combination tixagevimab/cilgavimab has received early access approval to reduce the frequency of symptomatic COVID-19 in immunocompromised patients at risk for severe COVID-19 and unresponsive to vaccination.We aim to evaluate the clinical efficacy of tixagevimab/cilgavimab in pre-exposure prophylaxis in patients with increased risk of severe COVID-19 in rheumatology.

Methods: In this multicenter observational study conducted between December 2021 and August 2022, we included patients with autoimmune or inflammatory diseases who received at least one intramuscular injection of tixagevimab/cilgavimab as pre-exposure prophylaxis in 3 French rheumatology units. Occurrence of COVID-19 was assessed during usual follow-up or by phone call. The endpoint was the incidence of COVID-19 and its severity.

Results: Tixagevimab/cilgavimab was administered to 115 patients, median age 62 years (52-71), with chronic arthritis (n=53), connective tissue disease (n=38) or vasculitis (n=11). The main background immunosuppressants were rituximab (n=98), methotrexate (n=48), mycophenolate mofetil (n=19), cyclophosphamide (n=15), azathioprine (n=12), and corticosteroids (n=62, median dose 5 mg, CI95% 5-8). During a median follow-up of 128 days (93-173), COVID-19 occurred in 23/115 patients (20%) with Omicron identified for the 8 genotyped patients. During the study period, the average weekly incidence was 1071 per 100.000 inhabitants in Ile-de-France vs. 588 per 100.000 in our patients. Patients who received a 2-injections regimen had a lower risk of infection than patients with a single injection (16/49, 33%, vs. 5/64, 8%, p=0.0012). The COVID-19+ patients did not differ from uninfected patients in terms of age, comorbidities, type and duration of underlying disease, extra-articular organ involvement or background immunosuppressants. All COVID-19 cases were non-severe, there were no deaths. The tolerance of injections was excellent, with no side effects observed.

Conclusion: In a population with autoimmune or inflammatory diseases at increased risk of severe COVID-19 with a poor response to vaccination, pre-exposure prophylaxis by tixagevimab/cilgavimab limited the risk of infection and the severity of COVID-19. This study supports the use of COVID-19 serological tests in this patient population in order to detect those who do not respond adequately to vaccination since pre-exposure treatments and/or early treatments are available.

Supporting image 1


Disclosures: M. THOMAS: None; M. MASSON: None; R. Seror: None; S. Bitoun: None; H. DUPUY: None; L. ESTIBALIZ: None; C. Richez: AbbVie/Abbott, 2, 6, Amgen, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 6, 12, receipt of drugs, GlaxoSmithKlein(GSK), 2, 6, Novartis, 2, 6, Pfizer, 2, 6; Y. ALLANORE: AbbVie/Abbott, 2, Alpine Immunoscience, 5, AstraZeneca, 2, Bayer, 2, Boehringer-Ingelheim, 2, Janssen, 2, Medsenic, 2, 5, Mylan, 2, OSE Immunotherapeutics, 5, Prometeus, 2, Roche, 2, Sanofi, 2; J. AVOUAC: AbbVie, 1, 2, 4, 6, BMS, 4, 5, 6, Fresenius Kabi, 4, 5, Galapagos, 1, 2, 4, 6, Lilly, 6, Novartis, 5, 6, Pfizer, 5, 6, Sanofi, 4, 6.

To cite this abstract in AMA style:

THOMAS M, MASSON M, Seror R, Bitoun S, DUPUY H, ESTIBALIZ L, Richez C, ALLANORE Y, AVOUAC J. Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19 [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/pre-exposure-prophylaxis-with-tixegvimab-cilgavimab-is-effective-in-limiting-the-risk-and-severity-of-covid-19-in-patients-with-auto-immune-or-inflammatory-diseases-at-increased-risk-of-severe-covid-1/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pre-exposure-prophylaxis-with-tixegvimab-cilgavimab-is-effective-in-limiting-the-risk-and-severity-of-covid-19-in-patients-with-auto-immune-or-inflammatory-diseases-at-increased-risk-of-severe-covid-1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology